A case of alveolar rhabdomyosarcoma showing concurrent responsive bone marrow lesions and refractory pancreatic lesions to pazopanib monotherapy

Pediatr Blood Cancer. 2020 Sep;67(9):e28323. doi: 10.1002/pbc.28323. Epub 2020 May 19.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Bone Density Conservation Agents / therapeutic use
  • Bone Marrow / pathology
  • Bone Marrow Neoplasms / drug therapy
  • Bone Marrow Neoplasms / secondary*
  • Fluorodeoxyglucose F18
  • Forkhead Box Protein O1 / genetics
  • Humans
  • Indazoles
  • Oncogene Proteins, Fusion / genetics
  • PAX3 Transcription Factor / genetics
  • Paired Box Transcription Factors / genetics
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / secondary*
  • Positron-Emission Tomography
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Rhabdomyosarcoma, Alveolar / drug therapy*
  • Rhabdomyosarcoma, Alveolar / pathology*
  • Sulfonamides / therapeutic use*
  • Tumor Microenvironment / drug effects
  • Zoledronic Acid / therapeutic use

Substances

  • Bone Density Conservation Agents
  • FOXO1 protein, human
  • Forkhead Box Protein O1
  • Indazoles
  • Oncogene Proteins, Fusion
  • PAX3 Transcription Factor
  • PAX3 protein, human
  • PAX3-FOXO1A fusion protein, human
  • Paired Box Transcription Factors
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Sulfonamides
  • Fluorodeoxyglucose F18
  • Zoledronic Acid
  • pazopanib
  • Receptors, Vascular Endothelial Growth Factor